ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2016
Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy.
Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- Stereotactic body radiation therapy for ultra-central lung malignancies: an updated systematic review and meta-analysis.Radiation oncology (London, England) · 2026Pooled it
- Clinical-radiomic model development for local recurrence prediction in stereotactic body radiation therapy-treated lung cancer: comparative analysis with radiobiological models.Scientific reports · 2026Article
- Translational tumor control probability modeling for NSCLC: A two-dimensional maximum-likelihood framework.Medical physics · 2026Article
- Comparative effectiveness of thermal ablation, radiotherapy, and surgery for adrenal metastases: a multi-institutional cohort study.European radiology · 2026Article
- Dosimetric comparison of scanned proton therapy and volumetric modulated arc therapy in isodose-prescribed stereotactic body radiotherapy for lung cancer.Journal of radiation research · 2026Article
- Perioperative risk stratification after resection of brain metastases: internal development and validation of the dominant lesion surgery score in a 20-year single-center cohort.Journal of neuro-oncology · 2026Article
- Machine learning-based prognostic model for local control prediction in lung cancer patients undergoing stereotactic body radiation therapy: a preliminary study.European journal of medical research · 2026Article
- Cold-spot driven local failure after stereotactic body radiation therapy for colorectal liver metastases.Frontiers in oncology · 2026Article
- In Silico Comparison of Photon Versus Proton Based Stereotactic Body Radiotherapy With Increasing Maximum Peak Dose for Treatment of Primary Renal Cell Carcinoma.International journal of particle therapy · 2025Article
- Development and validation of a nomogram for local control prediction in lung cancer patients treated with stereotactic body radiation therapy based on clinical, dosimetric, and inflammation-related parameters.BMC pulmonary medicine · 2025Article
- Stereotactic body radiotherapy for central non-small cell lung cancer: risk analysis of radiation pneumonitis and bronchial dose constraints.Journal of radiation research · 2025Article
- Article
- Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer.PloS one · 2025Article
- Metastasis-directed stereotactic radiotherapy in patients with breast cancer: results of an international multicenter cohort study.Clinical & experimental metastasis · 2024Article
- Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Incorporating the inflammation-related parameters enhances the performance of the nomogram for predicting local control in lung cancer patients treated with stereotactic body radiation therapy.Journal of cancer research and clinical oncology · 2024Article
- The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours.Clinical and translational radiation oncology · 2024Article
- External validation of radiobiological models for local control prediction in lung cancer patients treated with stereotactic body radiation therapy.Frontiers in oncology · 2024Article
- Radiotherapy as a metastasis directed therapy for liver oligometastases - comparative analysis between CT-guided interstitial HDR brachytherapy and two SBRT modalities performed on double-layer and single layer LINACs.Frontiers in oncology · 2024Article
- Dose prescription and reporting in stereotactic body radiotherapy: A multi-institutional study.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
26 authors at 20 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeTo evaluate whether local tumor control probability (TCP) in stereotactic body radiotherapy (SBRT) varies between lung metastases of different primary cancer sites and between primary non-small cell lung cancer (NSCLC) and secondary lung tumors. MATERIALS AND
methodsA retrospective multi-institutional (n=22) database of 399 patients with stage I NSCLC and 397 patients with 525 lung metastases was analyzed. Irradiation doses were converted to biologically effective doses (BED). Logistic regression was used for local tumor control probability (TCP) modeling and the second-order bias corrected Akaike Information Criterion was used for model comparison.
resultsAfter median follow-up of 19 months and 16 months (n.s.), local tumor control was observed in 87.7% and 86.7% of the primary and secondary lung tumors (n.s.), respectively. A strong dose-response relationship was observed in the primary NSCLC and metastatic cohort but dose-response relationships were not significantly different: the TCD90 (dose to achieve 90% TCP; BED of maximum planning target volume dose) estimates were 176 Gy (151-223) and 160 Gy (123-237) (n.s.), respectively. The dose-response relationship was not influenced by the primary cancer site within the metastatic cohort.
conclusionsDose-response relationships for local tumor control in SBRT were not different between lung metastases of various primary cancer sites and between primary NSCLC and lung metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.